ACE inhibitors can reverse blood vessel damage by Saxena, P.R. (Pramod Ranjan) & Man in 't Veld, A.J. (Arie)
ACE inhibitors can reverse blood vessel 
damage 
It is beginning to be recogrized 
that the goal of antihypertensive 
therapy is not mereiy to reduce 
blood pressure, but also to pte- 
vent - and even reverse - the 
damage to vessels and to organs’-’ 
associated with hypertension. 
Only in this way can one brealc 
out of the ‘vicious circle’ of hyper- 
tension and vascular and organ 
damage and overcome the wide- 
spread morbidity and mortality in 
hypertension-related heart dis- 
ease, cerebrovascular accidents 
and renal fail&. At a recent 
series of workshops*, the ceuses 
and consequences of end-organ 
and vessel wall damage, as weIl as 
the role of angiotensin I convert- 
ing enzyme (ACE) inhibitors, 
such as cilaxap&‘, were discussed. 
Hypertension and vessel wall 
damage 
A. Doyle (University of Mel- 
bourne) pointed out that hyper- 
tension is associated with prolif- 
eration and remodelling of the 
vascular smoot!? muscle cells. 
These changes are aggravated by 
atherosclerosis, leading to clinical 
consequences dependent on the 
end-organ affected: coronary 
atherosclerosis, angina, myo- 
cardial infarction and heart 
failure, renal insufficiency, and 
cerebrovascular accidents. The 
precise signal for the vascular 
changes is not well understood, 
but physical factors, mainly the 
increase in blood flow rather than 
of the pressure per se, seem to play 
an important role (M. Mulvany, 
University of Aarhus). Moreover, 
it is becoming clear that the vas- 
cular hypertrophy and tissue 
damage are related to the induc- 
tion of a number of growth factors 
(platelet-derived, epidermal and 
fibroblast growth factor&“), 
proto-oncogenes, and hormones 
(insJin, glucocorticoids and 
angiotensin II). Angiotensin II can 
promote growth in cell cuhnres by 
a variety of mech~anismr (M. Paul, 
Institute of High Blood Pressure 
Research, Heidelberg). 
Recent work has focused on the 
endothelium, which produces 
several vasoactive substances, in 
particular endothelium-derived 
relaxing factor. The inhibitory 
effects of the endothelium against 
vasoconstrictor stimuli decrease 
with age and hypertension (T. 
Liischer, University Hospital, 
Basel). 
Although it is relatively easy to 
determine the extent of vascular 
damage due to hypertension in 
experimental animals, this is 
much more ditficult in patients. 
However, the relationship be- 
tween blood pressure and arterial 
diameter or compliance can be 
used as an index of arterial stiff- 
ness and structural changes in 
humans (A. Simon, Broussais 
Hospital, Paris). Moreover, W. 
Birkenhhger (Erasmus University, 
Rotterdam) described several 
other parameters that can be used 
in situations such as clinical trials, 
where the available technological 
potentials have to be weighed 
against factors such as con- 
venience, compliance of trial sub- 
jects, and cost. 
Hypertension and the heart 
The changes that hypertension 
induces in the structure and hmc- 
tion of the heart and its associated 
vasculahire are clearly of great 
clinical significance, but which 
changes can best be used to pre- 
dict outcome and to direct ther- 
apy? In uncomplicated essential 
hypertensive patients, left ven- 
tricular hypertrophy emerged as a 
significant risk factor for future 
morbid events - independent of 
age, blood pressure or cardiac 
output (R. Fagard, University of 
Leuven). Although the left ven- 
tricular systolic function may be 
normal in hypertension, the di- 
astolic function is frequently 
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impaired (J. Rosenthal, University 
Medical Centre, Ulm). Another 
major risk factor in hypertension, 
particularly of the renovascular 
type. is the slowness of the re- 
sponse of the coronary blood flow 
to increasing myocardial demand. 
This ‘inappropriate’ 
blood flow appears to bt?:zzz 
to elevated angiotensin II levels 
(F. Magrini, University of Milan). 
Hypertension and the kidney 
Renal disease is both the cause 
and consequence of hypertension 
and the total avai!able g!omerular 
filtration area is the prime factor 
involved in the ‘vicious spiral’ of 
increasing high blood pressure 
and diminishing renal function. 
Therefore, the higher the micro- 
albuminurea, the higher the in- 
cidence of hypertension (B. M. 
Brenner, Harvard Medical School). 
While no therapy is available for 
directly increasing the number 
of glomeruli or the growth of 
glomerular capillaries, inter- 
ventions that control systemic and 
glomerular capillary hypertension 
could interrupt this cycle. 
Angiokrrsin and the brain 
Although the existence of a 
renin-angiotensin system has been 
established in several tissues, an 
appreciation of its importance, par- 
ticularly in the brain, is only now 
emerging. Ligand-binding stud- 
ies in the rat brain have identified 
two types of angiotensin receptor 
(see also Ref. 7): one located in the 
periventricular areas (AT, recep- 
tor) and the other in the mid- 
brain, brain stem and cerebellum 
(AT2 receptor). The majority of the 
pharmacological actions of angio- 
tensin in the periphery and, prob- 
ably, in the brain are mediated by 
AT, receptors, while the function 
of AT, receptors is not known (T. 
Unger. University of Heidelberg). 
8. llunnemann (Karolinska Insti- 
tute) reported that angiotensin 
fragments are released from nerve 
endings to activate postsynaptic 
receptors (‘hard-wired trans- 
mission), but they may also diffuse 
to adjacent areas or be released 
from glial cells to act on olher 
specific receptors (‘volume’ trans- 
mission). Among the several cm- 
tral effects of angiotensin 11, the 
increase in sympathetic activity 
is well recognized (P. R. Saxena, 
Erasmus University, Rotterdam), 
but the peptide may also disrupt 
cognitive functions (T. J. Williams, 
University of Bradford). 
ACE inhibition and vessel and 
oa;md=%e 
Beveral speakers addressed the 
question: does treatment with 
antihypertensive drugs, especially 
ACE inhibitors, reverse vessel and 
oqan damage in addition to lower- 
ing blood pressure? Reviewing 
the limtted data available on this 
subject, Doyle pointed out that 
methyldopa and, particularly, 
ACE inhibitors can generally 
reverse or prevent the cardiac 
hypertrophy, vascular prolifer- 
ation and renal damage associated 
with experimental and clinical 
hypertension, but antihyperten- 
sive drugs such as hydralazine, 
prazosin and B-admnoceptor 
antagonists usually fail to do so. 
Simon reported that in hyperten- 
sive subjects no active or passive 
changes in arterial compliance are 
observed after treatment with 
ketanserin or urapidil, but the 
Ca*+ channel blockers nitren- 
dipine and nicardipine acttvely 
increase compliance as well as 
larue arterv diameter. W. H. Van , 
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Gilst (University of Groningen) 
reported that ACE inhibitors in- 
crease coronary blood flow in the 
rat isolated heart; it is, however, 
unclear whether these effects are 
due to a decrease in angiotensin II 
or to an increase in bradykinin 
concentration in the heart. ln 
humans, although the effects of 
ACE inhibitors on coronary blood 
flow per se may not be consistent, 
these drugs do antagonize exer- 
cise-induced coronary vasocon- 
striction (Magrini). 
In patients with renovascular 
hypertension, particularly those 
with bilateral stenosis or stenosis 
of a solitary kidney, the use of 
ACE inhibitors may be associated 
with a reversible deterioration 
of renal function (A. Mimran, 
Lepeyronie Hospital, MontPelier). 
However, these drugs cause fewer 
metabolic side-e&c& in patients 
with diabekic nephmpathy (M. 
Beaufils, Tenon Hospital, Paris) 
and they lower urinary protein 
leakage by decmasing intra- 
glomerular pressure, both in 
diabetic and non-diabetic renal 
disease (P. E. de Jong, Academic 
Medical Hospital, 
GroY#enand H. H. Parving, Hvideue ospital, 
Rkqenbo%, C%enhsgcn). 
In the Cl%, Williams reported 
that ACE inhibitors can improve 
both basal and impaired (e.g. by 
scopolamine or nucleus basalis 
lesion) cognitive function in 
rodents; this improvement seems 
to be related in part to acetyl- 
choline release in the brain. In 
humans, the data tqgest that 
impairment, whereas @adreno- 
ceptor anbqonists are only weakly 
impEcated and ACE inhibitors are 
least likely to affect cognitive 
function (C. J. Bulpitt, Royal Post- 
graduate Medical school, London). 
Preclinical data on the new ACE 
inhibitor cilazapril, which has a 
potent antihypertensive effect in 
both experimental animals and 
humans, demonstrated that 
chronic administration to spon- 
taneously hyperknsive rats de- 
creases cardiac mass, increases 
coronary and cerebral vascular 
reserve, and prevents and mverses 
media hypertrophy in, for ex- 
ample, the coronary, mesenteric, 
renal and carotid vascular beds 
(J-P._Clozel, Hoffmann& Roche; 
see Fig. 1). Moreover, in the rat 
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carotid artery, the drug reduces 
myointimal proliferation associ- 
ated with balloon catheterization, 
suggesting that cilazapril may also 
prevent re-stenosis in cardiac 
patients subjected to percutaneous 
transluminal coronary angio- 
p&y. The results of an ongoing 
clinical trial with cilazapril 
(MERCATOR: Multicentre Euro- 
pean Research trial with Cilazapril 
after Angioplasty to prevent 
Transluminal coronary Obstruc- 
tion and Re-stenosis) are awaited. 
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Specificity in the recognition 
process between charged carbohydrates 
and proteins 
T.t .?nt research on glycocon- 
jugates (e.g. glycolipids and 
glycoproteins) has revealed the 
important role that carbohydrate 
moieties may play in specific 
interactions with protein@. This 
type of recognition phenomenon 
triggers various biological pro- 
cesses such as the adhesion of 
pathogens to cells, regulation of 
the activity of pmtease inhibitors, 
reactions between antigens and 
antibodies, fertilization, endo- 
cvtosis and cell differentiation13 
(k&Reviewartldepp.~272). 
In higher organisms, the glycos- 
aminc$ycans~are part of larger 
utr\l+n9lvcan molecules3. Thev are 
tocate$ ‘mainly in extraceriular 
matrices and at cell surfaces, and 
interact strongly with a broad 
range of proteins (e.g. growth 
factors, lipoproteins, complement 
components, cell-attachment 
glycopmteins and pmtease in- 
hibitors)“. These high molecular 
mass (50-100 bDa) polyanionic 
polysac&arldes are divided into 
different classes according to their 
carbohydrate composition (hep- 
arin, heparan sulphate, dermatan 
sulphate, chondmitin sulphate, 
hyahuonic acid and keratan sul- 
phate). Within each class, further 
structural diversity can occur 
through variation of specific 
carbohydate residues and by 
varying the position of N-acetyl 
and N,O-sulphate gmups3”b. The 
polysaccharide chain of glycos- 
aminoglycans consists of long 
stretches of structurally well- 
defined alternating sequences, 
together with small he@mgeneous 
domain&‘. These domains are 
most likely to confer functional 
specific@ for protein interactions. 
For example, in the heparin- 
antithmmbin III interaction, bind- 
ing of heparin induces a confor- 
mational change in antithmmbin 
III, thereby accelerating the 
inactivation of blood coagulation 
factors (e.g. factor IIa and factor 
Xa) mediated by antithmmbin 
III. Approximately 80% of the 
heparin molecule consists of 
a repeating disaccharide unit 
(cu+idoWranosyluronic acid-l-sul- 
phate and 2-deoxy-2-sulphamino- 
a-o-glucopyranose-6-sulphate, 
each of which is glycosidically 
linked through position 4; Ref. 6), 
while the rest of the molecule is 
heterogeneous and incorporates 
other types of saccharides such as 
D-glucumnic acid. 
The findine that a hetem- 
geneous pentasaccharide region 
of heparin activates the pmtease 
inhibitor antithmmbin III chal- 
lenged the widespread assump- 
tion that the bioactivity of heparin 
(and probably of other glycos- 
aminoglycans) might be due to its 
polyanionic character. The speci- 
ficity of the interaction of the 
sulphated pentasaccharide with 
the protein (see Fig. 1) became 
apparent when heparin pentasac- 
charide analogues were syn- 
thesized and tested for inhibition 
of blood coagulation factor Xa’@13. 
The presence and spatial orien- 
tation14J5 of particular sulphate 
and carboxylate groups (high- 
lighted in red in Fig. 1) were 
shown to be essential for bio- 
logical activity. Moreover, essen- 
tial sulphate groups cannot be 
replaced by phosphate groups16. 
Analogues in which only one 
chiral centre has been inverted 
(indicated by # in Fig. 1) were 
found to be inactive (M. Petitou 
and C. A. A. van Boeckel, unpub- 
lished), while the presence of a 
rigid carbohydrate moiety (i.e. the 
glucumnic acid unit) may be as 
important as the presence of 
the essential charged gmups’7. 
Furthermor:, analogues with extra 
sulphate groups may become less 
active (particularly unfavourable 
is a sulphate group at the 3-O 
position of the glucumnic acid 
unit, C. A. A. van Boeckel, un- 
published), while additional sul- 
phation at one particular position, 
the 3-O at the reducing end unit 
(indicated by an asterisk in Fig. l), 
provides the most potent ma- 
logue found so far, 0RC31550’6~‘9. 
The heuristics described above 
indicate that for a good interaction 
with antithmmbin III the pmta- 
saccharide must adhere to very 
stringent criteria imposed by the 
three-dimensional structure of the 
protein. However, no crystallo- 
graphic studies have yet been 
reported from which such specific 
pmtein-gIycosaminoglycan inter- 
actions can be visualized. Indeed, 
there is a paucity of three-dimen- 
sional information on carbo- 
hydrate-protein interactions in 
general, and studies to date have 
